Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.
Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.
Immunity. 2018 Jun 19;48(6):1077-1080. doi: 10.1016/j.immuni.2018.06.003.
Four studies recently reported in the New England Journal of Medicine highlight advances in treatment with immune checkpoint blockade across the cancer care continuum. These findings demonstrate efficacy of these agents in the treatment of early and late-stage disease, as monotherapy or in combination, and in addition to-or in place of-standard front-line therapy.
四项最近发表在《新英格兰医学杂志》上的研究强调了免疫检查点阻断在癌症治疗全程中的治疗进展。这些发现表明这些药物在单药或联合治疗早期和晚期疾病、作为标准一线治疗的附加或替代治疗方面具有疗效。